Complete financial analysis of Forte Biosciences, Inc. (FBRX) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Forte Biosciences, Inc., a leading company in the Biotechnology industry within the Healthcare sector.
You may be interested
- Shilchar Technologies Limited (SHILCTECH.BO) Income Statement Analysis – Financial Results
- Reko International Group Inc. (REKO.V) Income Statement Analysis – Financial Results
- Pyramid AG (M3BK.DE) Income Statement Analysis – Financial Results
- Chavant Capital Acquisition Corp. (CLAYW) Income Statement Analysis – Financial Results
- Media Asia Group Holdings Limited (8075.HK) Income Statement Analysis – Financial Results
Forte Biosciences, Inc. (FBRX)
About Forte Biosciences, Inc.
Forte Biosciences, Inc. operates as a clinical-stage biopharmaceutical company in the United States. It is developing FB-102 program that addresses various autoimmune diseases, such as vitiligo and alopecia areata. The company is headquartered in Dallas, Texas.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 18.04M | 41.00K | 49.00K | 51.00K |
| Cost of Revenue | 9.00K | 0.00 | 36.00K | 54.00K | 11.00K | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | -9.00K | 0.00 | -36.00K | -54.00K | -11.00K | 18.04M | 41.00K | 49.00K | 51.00K |
| Gross Profit Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 100.00% | 100.00% | 100.00% | 100.00% |
| Research & Development | 21.86M | 5.59M | 13.85M | 10.00M | 2.68M | 50.46M | 29.11M | 27.22M | 19.17M |
| General & Administrative | 10.62M | 8.30M | 7.63M | 4.22M | 1.38M | 265.68K | 8.56M | 4.52M | 3.83M |
| Selling & Marketing | -9.00K | 0.00 | 0.00 | 0.00 | 0.00 | 12.54M | -292.00K | -255.00K | -232.00K |
| SG&A | 10.62M | 8.30M | 7.63M | 4.22M | 1.38M | 12.81M | 8.27M | 4.27M | 3.60M |
| Other Expenses | -1.00 | 17.00K | -222.00K | -205.00K | -6.85K | 0.00 | 0.00 | -50.00K | 0.00 |
| Operating Expenses | 32.48M | 13.90M | 21.49M | 14.23M | 4.06M | 63.26M | 37.38M | 31.49M | 22.77M |
| Cost & Expenses | 32.49M | 13.90M | 21.49M | 14.23M | 4.06M | 63.89M | 37.67M | 31.74M | 23.01M |
| Interest Income | 1.12M | 0.00 | 0.00 | 0.00 | 0.00 | 595.00K | 0.00 | 0.00 | |
| Interest Expense | 0.00 | 0.00 | 0.00 | 0.00 | 173.38K | 1.93M | -1.84M | -102.00K | |
| Depreciation & Amortization | 9.00K | 36.00K | 36.00K | 54.00K | 11.00K | 625.00K | 292.00K | 255.00K | 232.00K |
| EBITDA | -32.48M | -13.90M | -21.45M | -46.43M | -4.05M | -43.69M | -36.71M | -31.17M | -22.49M |
| EBITDA Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | -250.77% | -91,065.85% | -64,155.10% | -44,552.94% |
| Operating Income | -32.49M | -13.90M | -21.49M | 17.83M | -4.06M | -45.85M | -37.63M | -31.69M | -22.95M |
| Operating Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | -254.23% | -91,778.05% | -64,675.51% | -45,007.84% |
| Total Other Income/Expenses | 1.01M | 17.00K | -222.00K | -205.00K | -5.00K | -1.40M | -1.30M | -1.79M | -102.00K |
| Income Before Tax | -31.48M | -13.88M | -21.71M | -46.49M | -4.07M | -47.26M | -38.93M | -33.48M | -23.06M |
| Income Before Tax Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | -262.01% | -94,948.78% | -68,322.45% | -45,207.84% |
| Income Tax Expense | 0.00 | -17.00K | -200.56K | 32.06M | -2.52K | 1.70M | -2.60M | -3.67M | -204.00K |
| Net Income | -31.48M | -13.86M | -21.71M | -78.54M | -4.07M | -48.96M | -38.93M | -33.48M | -23.06M |
| Net Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | -271.43% | -94,948.78% | -68,322.45% | -45,207.84% |
| EPS | -24.92 | -19.96 | -38.85 | -157.93 | -48.25 | -915.18 | -997.50 | -634.80 | -474.15 |
| EPS Diluted | -24.92 | -19.96 | -38.85 | -157.93 | -48.25 | -915.18 | -997.50 | -634.80 | -474.15 |
| Weighted Avg Shares Out | 1.26M | 695.34K | 558.71K | 294.36K | 84.33K | 53.49K | 38.95K | 52.74K | 48.63K |
| Weighted Avg Shares Out (Dil) | 1.26M | 695.34K | 558.71K | 294.36K | 84.33K | 53.49K | 38.95K | 52.74K | 48.63K |
Forte Biosciences, Inc. to Announce Third Quarter 2020 Results on November 9
TORRANCE, Calif.--(BUSINESS WIRE)--Forte Biosciences, Inc. (www.fortebiorx.com) (NASDAQ: FBRX), a clinical-stage biopharmaceutical company, today announced that it will release third quarter 2020 results after the market close on November 9, 2020 and will host a conference call at 4:30 pm ET...
Forte Biosciences, Inc. to Announce Third Quarter 2020 Results on November 9
TORRANCE, Calif.--(BUSINESS WIRE)--Forte Biosciences, Inc. (www.fortebiorx.com) (NASDAQ: FBRX), a clinical-stage biopharmaceutical company, today announced that it will release third quarter 2020 results after the market close on November 9, 2020 and will host a conference call at 4:30 pm ET...
Forte Biosciences Announces Closing of $46.0 Million Public Offering of Common Stock and Full Exercise of Underwriters’ Option to Purchase Additional Shares
TORRANCE, Calif.--(BUSINESS WIRE)--Forte Biosciences, Inc. (NASDAQ: FBRX), a clinical-stage biopharmaceutical company, announced today the closing of its previously announced underwritten public offering of an aggregate of 1,614,035 shares of its common stock, which includes 210,526 shares sold upon the full...
Forte Biosciences Announces Closing of $46.0 Million Public Offering of Common Stock and Full Exercise of Underwriters' Option to Purchase Additional Shares
TORRANCE, Calif.--(BUSINESS WIRE)--Forte Biosciences, Inc. (NASDAQ: FBRX), a clinical-stage biopharmaceutical company, announced today the closing of its previously announced underwritten public offering of an aggregate of 1,614,035 shares of its common stock, which includes 210,526 shares sold upon the full...
Forte Biosciences Announces Pricing of $40.0 Million Public Offering of Common Stock
TORRANCE, Calif.--(BUSINESS WIRE)--FORTE BIOSCIENCES ANNOUNCES PRICING OF $40.0 MILLION PUBLIC OFFERING OF COMMON STOCK
Forte Biosciences Announces Pricing of $40.0 Million Public Offering of Common Stock
TORRANCE, Calif.--(BUSINESS WIRE)--Forte Biosciences, Inc. (NASDAQ: FBRX), a clinical-stage biopharmaceutical company, today announced the pricing of an underwritten public offering of 1,403,509 shares of its common stock at a price to the public of $28.50 per share. In addition, Forte...
Forte Biosciences Announces Proposed Public Offering of Common Stock
TORRANCE, Calif.--(BUSINESS WIRE)--Forte Biosciences, Inc. (www.fortebiorx.com) (NASDAQ: FBRX), a clinical-stage biopharmaceutical company, today announced that it has commenced an underwritten public offering of its common stock. In addition, Forte expects to grant the underwriters a 30-day option to purchase up...
Forte Biosciences Announces Proposed Public Offering of Common Stock
TORRANCE, Calif.--(BUSINESS WIRE)--Forte Biosciences, Inc. (www.fortebiorx.com) (NASDAQ: FBRX), a clinical-stage biopharmaceutical company, today announced that it has commenced an underwritten public offering of its common stock. In addition, Forte expects to grant the underwriters a 30-day option to purchase up...
Forte Biosciences, Inc. Announces the FDA Has Granted Fast Track Designation to FB-401 for the Treatment of Atopic Dermatitis
TORRANCE, Calif.--(BUSINESS WIRE)--Forte Biosciences, Inc. (www.fortebiorx.com) (NASDAQ: FBRX), a clinical-stage biopharmaceutical company, today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track Designation to FB-401 for the treatment of atopic dermatitis. FB-401 is a topically applied...
Forte Biosciences, Inc. Announces the FDA Has Granted Fast Track Designation to FB-401 for the Treatment of Atopic Dermatitis
TORRANCE, Calif.--(BUSINESS WIRE)--Forte Biosciences, Inc. (www.fortebiorx.com) (NASDAQ: FBRX), a clinical-stage biopharmaceutical company, today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track Designation to FB-401 for the treatment of atopic dermatitis. FB-401 is a topically applied...
Source: https://incomestatements.info
Category: Stock Reports